EP0358665A1 - Pharmaceutical compositions having spasmolytic activity - Google Patents
Pharmaceutical compositions having spasmolytic activityInfo
- Publication number
- EP0358665A1 EP0358665A1 EP88903795A EP88903795A EP0358665A1 EP 0358665 A1 EP0358665 A1 EP 0358665A1 EP 88903795 A EP88903795 A EP 88903795A EP 88903795 A EP88903795 A EP 88903795A EP 0358665 A1 EP0358665 A1 EP 0358665A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical compositions
- idanpramine
- sulfate
- compositions according
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
Definitions
- the present invention relates to pharmaceutical compositions containing as the active ingredient (1-(2-piperidinoethyl)-4 ,4-bis-(4-methoxyphenyl)-2,5-imi- dazolidinedione (i.e. idanpramine) sulfate, and to the use thereof in human therapy.
- hydrochloride salt which is easy and economic to prepare, has been hitherto used for the preparation of suitable pharmaceutical formulation; however, the cha ⁇ racteristics of said salts are not perfectly suited for the envisaged pharmaceutical uses.
- a particularly preferred object of the invention is provided by capsules or tablets in which the active ingredient is slowly and gradually released during time.
- idanpramine sulfate can be prepared by means of per se known methods.
- idanpramine sulfate can be obtained by trea ⁇ ting an aqueous or aqueous-alcoholic solution or suspen ⁇ sion of idanpramine base with sulfuric acid, recovering the salt by precipitation with a non-solvent, by lyophi- lization or similar techniques.
- the techniques and the excipients used for the pre ⁇ paration of- the pharmaceutical compositions are those described, for instance, in "Remington's Pharmaceutical Sciences Handbook",hack Pub. Co., New York, USA.
- examples of formulations comprise capsule, sugar-coated pills, drops, solutions, syrups, vials, suppositories, rectal capsules, granulates, lozenges.
- compositions of the invention will possibly contain other active ingredients having complementary, synergic or anyhow useful activities.
- Unitary dosages will usually contain 50 to 200 mg of idanpramine sulfate, and will be administered 1 to 3 times a day, depending on the conditions of the patient and the severity of the disease. The following non-limiting examples further illu ⁇ strate the invention.
- Each rectal capsule contains:
- Each vial contains
- Each 10 ml ampoule contains Active ingredient:
- a mixture comprising 75% saccharose and 25% maize starch was placed into a stainless steel rotary pan; while the rotary pan rotated, water was sprayed on the mixture, in an amount of 15% w/w based on the total mass, thus obtaining spherical granules of different sizes.
- a predetermined amount of spherical nuclei was placed into a special rotary stainless steel pan rotating at moderate speed.
- the drug was distributed on the granules by means of a suited binding solution.
- the whole operation was carried out slowly so as to avoid as much as possible the formation of clots; when the predetermined amount of active principle has been applied, the granules were sieved through a 1340.u sieve and then dried at 35°C with forced ventilation.
- d) Application of the delaying membrane on the granules The granules obtained in c) were placed again in rotary pan. The delaying membrane was applied on them, slowly, keeping the pan at moderate speed and portion- wise, so as to obtain a uniform distribution of the coating on the granules surface; the product was dried with talc portions between each application.
- the application of the membrane was normally carried out in more than a phase, up to the obtainment of the desired i ⁇ vitro release values.
- the granules were dried by insufflating air at 35 ⁇ C into the rotating pan, till the content of the residual solvents is within the predetermined limits.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT8720229A IT1215441B (it) | 1987-04-23 | 1987-04-23 | Composizioni farmaceutiche adattivita' spasmolitica contenente come principio attio idanpramina |
IT2022987 | 1987-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0358665A1 true EP0358665A1 (en) | 1990-03-21 |
Family
ID=11164959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88903795A Withdrawn EP0358665A1 (en) | 1987-04-23 | 1988-04-15 | Pharmaceutical compositions having spasmolytic activity |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0358665A1 (ko) |
JP (1) | JPH03500163A (ko) |
KR (1) | KR890700580A (ko) |
AU (1) | AU1685088A (ko) |
IT (1) | IT1215441B (ko) |
WO (1) | WO1988008421A1 (ko) |
-
1987
- 1987-04-23 IT IT8720229A patent/IT1215441B/it active
-
1988
- 1988-04-15 EP EP88903795A patent/EP0358665A1/en not_active Withdrawn
- 1988-04-15 WO PCT/EP1988/000318 patent/WO1988008421A1/en not_active Application Discontinuation
- 1988-04-15 JP JP63503658A patent/JPH03500163A/ja active Pending
- 1988-04-15 AU AU16850/88A patent/AU1685088A/en not_active Abandoned
- 1988-04-15 KR KR1019880701708A patent/KR890700580A/ko not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO8808421A1 * |
Also Published As
Publication number | Publication date |
---|---|
IT1215441B (it) | 1990-02-14 |
IT8720229A0 (it) | 1987-04-23 |
KR890700580A (ko) | 1989-04-25 |
AU1685088A (en) | 1988-12-02 |
WO1988008421A1 (en) | 1988-11-03 |
JPH03500163A (ja) | 1991-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0097523B1 (en) | Extended action controlled release compositions | |
US4248858A (en) | Sustained release pharmaceutical compositions | |
FI92904B (fi) | Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi | |
RU1816213C (ru) | Способ получени твердой лекарственной формы с регулируемым выделением лекарственного средства | |
US5051263A (en) | Controlled-release formulations | |
GB2056278A (en) | Sustained release compositions | |
PL142312B1 (en) | Process for preparing delayed-action preparation with bromohexyne | |
WO1988003796A1 (en) | Controlled release indomethacin | |
IE60605B1 (en) | 3'-azido-3'-deoxythymidine controlled-release formulations | |
EA014707B1 (ru) | Новая форма введения рацекадотрила | |
JPH07300417A (ja) | 抗うつまたは抗パーキンソン病薬 | |
EP0264989A1 (en) | Galenic formulations for oral use of rhein derivatives with delayed release for therapeutical use | |
CA2216277C (en) | Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance | |
EP1154762A1 (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
WO1989002738A1 (en) | Sustained-release nifedipine formulation | |
CA1069441A (en) | Pharmaceutical composition containing 2,1,3-benzothiazole | |
US4428951A (en) | Long acting pharmaceutical composition | |
GB2047096A (en) | Naftidrofuryl composition for immediate and delayed release | |
EP0358665A1 (en) | Pharmaceutical compositions having spasmolytic activity | |
JPH11335302A (ja) | 安定な医薬組成物 | |
JPH01313431A (ja) | ジルチアゼム・マイクロビーズ、その製法および徐放性医薬組成物 | |
CA1331568C (en) | Pharmaceutical composition containing dihydropyridine-dianhydrohexitol and nitro derivative | |
HUT70759A (en) | Stabile pharmaceutical compositions containing ipsapiron having retard effect | |
JPS5942318A (ja) | 製薬組成物、その製造法及び応用 | |
RU2212231C1 (ru) | Фармацевтическая композиция, обладающая анаболическим действием |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19891018 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19921105 |